Summary
1,027.45 18.07(1.79%)12/12/2025
Eli Lilly and Company (LLY)
LLY reported last earnings on 2025-10-30 after the market. An EPS of $7.02 was observed compared to an estimated EPS of $5.69, resulting in a surprise value of $1.33. A revenue of $17,601 million was observed compared to an estimated revenue of $16,053 million, resulting in a surprise value of $1,548 Million.
Eli Lilly and Company (LLY)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years |
| 1.79 | 5.96 | 33.96 | 50.41 | 52.99 | 41.09 | 690.05 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan!
Fundamental Ratings
| Category | Rating |
| Main Rating | B |
| Recommended Rating | Neutral |
| DCF | Buy |
| ROE | Strong Buy |
| ROA | Strong Buy |
| Debt/Equity | Strong Sell |
| P/E | Strong Sell |
| P/B | Strong Sell |
Earnings
| Trading Data | ||
| Close | 1,027.45 | |
| Open | 1,008.76 | |
| High | 1,028.90 | |
| Low | 1,003.50 | |
| Volume | 2,481,936 | |
| Change | 18.07 | |
| Change % | 1.79 | |
| Avg Volume (20 Days) | 4,633,426 | |
| Volume/Avg Volume (20 Days) Ratio | 0.54 | |
| 52 Week Range | 627.12 - 1,111.11 | |
| Price vs 52 Week High | -7.53% | |
| Price vs 52 Week Low | 63.84% | |
| Range | 0.00 | |
| Gap Up/Down | -9.11 | |
Profitibility | ||
| Market Capitalization (Mln) | 870,568 | |
| Revenue per share | 66.2502 | |
| Net Income per share | 20.5286 | |
| Dividend Yield | 0.0059 | |
| Dividend Share | 600.00% | |
Valuations | ||
| Enterprise Value | 0.00% | |
| PE Ratio | 49.1578 | |
| PB Ratio | 0.0000 | |
| PTB Ratio | 0.0000 | |
Liquidity | ||
| Debt/Equity Ratio | 0.0000 | |
| Net Debt/EBIDTA Ratio | 0.0000 | |
| Current Ratio | 0.0000 | |
Enterprise Value and Cash Flow | ||
| EV/Sales Ratio | 0.0000 | |
| EV/EBIDTA Ratio | 0.0000 | |
| EV/Free Cash Flow Ratio | 0.0000 | |
12/12 13:41 EST - feeds.benzinga.com
New Eli Lilly Results Suggest Major Delay To Chemotherapy For Breast Cancer Patients
Eli Lilly and Co shared updated results of Inluriyo (imlunestrant) from a Phase 3 study in previously treated breast cancer patients.
New Eli Lilly Results Suggest Major Delay To Chemotherapy For Breast Cancer Patients
Eli Lilly and Co shared updated results of Inluriyo (imlunestrant) from a Phase 3 study in previously treated breast cancer patients.
12/12 12:20 EST - zacks.com
Eli Lilly's Next-Generation Obesity Drug Secures First Phase III Win
LLY's retatrutide posts strong weight-loss and pain-reduction results in its first Phase III study, boosting investor optimism.
Eli Lilly's Next-Generation Obesity Drug Secures First Phase III Win
LLY's retatrutide posts strong weight-loss and pain-reduction results in its first Phase III study, boosting investor optimism.
12/12 11:45 EST - prnewswire.com
Updated data for Lilly's Inluriyo™ (imlunestrant) reinforce efficacy results as monotherapy and in combination with Verzenio® (abemaciclib) in ER+, HER2- advanced breast cancer
As monotherapy, imlunestrant demonstrated an 11.4-month numeric improvement in median OS versus endocrine therapy in patients with ESR1-mutated disease In all patients, the imlunestrant plus abemaciclib combination achieved a median PFS of 10.9 months, demonstrated a favorable OS trend, and...
Updated data for Lilly's Inluriyo™ (imlunestrant) reinforce efficacy results as monotherapy and in combination with Verzenio® (abemaciclib) in ER+, HER2- advanced breast cancer
As monotherapy, imlunestrant demonstrated an 11.4-month numeric improvement in median OS versus endocrine therapy in patients with ESR1-mutated disease In all patients, the imlunestrant plus abemaciclib combination achieved a median PFS of 10.9 months, demonstrated a favorable OS trend, and...
12/12 11:04 EST - investors.com
Eli Lilly Rises, Again, After EMA Recommends Mounjaro For Children As Young As 10
On Friday, Europe's drug regulator recommended extending the use of Eli Lilly's type 2 diabetes drug, Mounjaro, to children as young as 10.
Eli Lilly Rises, Again, After EMA Recommends Mounjaro For Children As Young As 10
On Friday, Europe's drug regulator recommended extending the use of Eli Lilly's type 2 diabetes drug, Mounjaro, to children as young as 10.
12/12 08:10 EST - 247wallst.com
Eli Lilly (NYSE: LLY) Stock Price Prediction and Forecast 2025-2030 (Dec 2025)
From late 2020 to the summer of 2024, Eli Lilly & Co. (NYSE: LLY) stock was on a tear, up more than 635%, before taking a breather and then heading higher.
Eli Lilly (NYSE: LLY) Stock Price Prediction and Forecast 2025-2030 (Dec 2025)
From late 2020 to the summer of 2024, Eli Lilly & Co. (NYSE: LLY) stock was on a tear, up more than 635%, before taking a breather and then heading higher.
12/12 07:38 EST - gurufocus.com
First Look: Lululemon shake-up, Broadcom AI jitters, Costco beat
Stock News Lululemon leadership change lifts shares: Lululemon Athletica (LULU) said CEO Calvin McDonald will step down Jan. 31, with CFO Meghan Frank and CCO A
First Look: Lululemon shake-up, Broadcom AI jitters, Costco beat
Stock News Lululemon leadership change lifts shares: Lululemon Athletica (LULU) said CEO Calvin McDonald will step down Jan. 31, with CFO Meghan Frank and CCO A
12/12 07:30 EST - fool.com
Breakfast News: Broadcom Guides Lower
Broadcom feels the heat of AI expectations, LULU soars over 10% on strong results, and more
Breakfast News: Broadcom Guides Lower
Broadcom feels the heat of AI expectations, LULU soars over 10% on strong results, and more
12/12 06:42 EST - fool.com
Think Eli Lilly Is Expensive? This Metric Says Otherwise.
Eli Lilly's shares may appear expensive at first glance, but a closer look reveals a different story. The company's outlook is strong, and the stock is a buy, even at current levels.
Think Eli Lilly Is Expensive? This Metric Says Otherwise.
Eli Lilly's shares may appear expensive at first glance, but a closer look reveals a different story. The company's outlook is strong, and the stock is a buy, even at current levels.
12/11 17:35 EST - gurufocus.com
Market Today: Fed Cut, Oracle Slide, Broadcom AI Surge
Stock News Oracle sinks, ripples across AI trade: Oracle (ORCL) fell about 11% after a revenue miss and heavier AI capex drove negative free cash flow, pressuri
Market Today: Fed Cut, Oracle Slide, Broadcom AI Surge
Stock News Oracle sinks, ripples across AI trade: Oracle (ORCL) fell about 11% after a revenue miss and heavier AI capex drove negative free cash flow, pressuri
12/11 17:26 EST - youtube.com
Thursday's Final Takeaways: LLY Positive Drug Trial, Home Prices Turn Negative
Marley Kayden and Sam Vadas discuss Eli Lilly's (LLY) positive weight loss drug trial and how home prices turned negative. They also note that jobless claims rose and the trade deficit narrowed.
Thursday's Final Takeaways: LLY Positive Drug Trial, Home Prices Turn Negative
Marley Kayden and Sam Vadas discuss Eli Lilly's (LLY) positive weight loss drug trial and how home prices turned negative. They also note that jobless claims rose and the trade deficit narrowed.
12/11 12:00 EST - investopedia.com
Dow Jones Today: Dow Sets All-Time High But Nasdaq, S&P 500 Fall as Oracle Results Drag AI Shares
Major stock indexes were mixed Thursday, with the Dow Jones Industrial Average setting a new all-time high but the Nasdaq and S&P 500 falling as Oracle results dragged AI-tied shares.
Dow Jones Today: Dow Sets All-Time High But Nasdaq, S&P 500 Fall as Oracle Results Drag AI Shares
Major stock indexes were mixed Thursday, with the Dow Jones Industrial Average setting a new all-time high but the Nasdaq and S&P 500 falling as Oracle results dragged AI-tied shares.
12/11 11:23 EST - barrons.com
Eli Lilly's Latest Obesity Drug Delivers Strong Results. It Might Work Too Well.
The company said some patients had dropped out of the trial because they felt they were losing too much weight.
Eli Lilly's Latest Obesity Drug Delivers Strong Results. It Might Work Too Well.
The company said some patients had dropped out of the trial because they felt they were losing too much weight.
12/11 11:16 EST - schaeffersresearch.com
2 Pharma Stocks Pop on Strong Obesity Drug Trial Results
Positive drug trial results are boosting pharmaceutical stocks today, with Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP) and Eli Lilly & Co. (NYSE:LLY) drawing investor attention after encouraging developments for their latest obesity drugs.
2 Pharma Stocks Pop on Strong Obesity Drug Trial Results
Positive drug trial results are boosting pharmaceutical stocks today, with Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP) and Eli Lilly & Co. (NYSE:LLY) drawing investor attention after encouraging developments for their latest obesity drugs.
12/11 11:15 EST - globenewswire.com
Prison Fellowship Awarded $5 Million Grant From Lilly Endowment Inc. To Broaden Its Reach in Sharing Stories of Radical Restoration
WASHINGTON, D.C., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Prison Fellowship, the nation's largest Christian nonprofit serving currently and formerly incarcerated people and their families and a leading advocate for criminal justice reform, today announced that it has been awarded a $5 million grant from...
Prison Fellowship Awarded $5 Million Grant From Lilly Endowment Inc. To Broaden Its Reach in Sharing Stories of Radical Restoration
WASHINGTON, D.C., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Prison Fellowship, the nation's largest Christian nonprofit serving currently and formerly incarcerated people and their families and a leading advocate for criminal justice reform, today announced that it has been awarded a $5 million grant from...
12/11 10:59 EST - youtube.com
New Lilly Shot Reduces Body Weight by 23% in Study
A next-generation obesity shot from Eli Lilly helped patients lose nearly a quarter of their body weight, potentially making the experimental drug the most potent weight-loss medicine yet. Madison Muller reports on Bloomberg Television.
New Lilly Shot Reduces Body Weight by 23% in Study
A next-generation obesity shot from Eli Lilly helped patients lose nearly a quarter of their body weight, potentially making the experimental drug the most potent weight-loss medicine yet. Madison Muller reports on Bloomberg Television.
12/11 10:21 EST - proactiveinvestors.com
Eli Lilly reports positive Phase 3 trial results for obesity drug retatrutide
Eli Lilly and Co (NYSE:LLY) has reported positive topline results from its Phase 3 TRIUMPH-4 trial evaluating its obesity treatment retatrutide in adults with obesity and knee osteoarthritis. The investigational drug, a once-weekly injectable targeting GLP‑1, GIP, and glucagon receptors, is...
Eli Lilly reports positive Phase 3 trial results for obesity drug retatrutide
Eli Lilly and Co (NYSE:LLY) has reported positive topline results from its Phase 3 TRIUMPH-4 trial evaluating its obesity treatment retatrutide in adults with obesity and knee osteoarthritis. The investigational drug, a once-weekly injectable targeting GLP‑1, GIP, and glucagon receptors, is...
12/11 10:15 EST - youtube.com
GOOGL Price Target Raise, SNPS Strong Guidance, LLY Retratrutide Results
Oracle (ORCL) weighed on markets Thursday morning but Diane King Hall turns to stocks seeing strength. Synopsys (SNPS) added muscle to the tech trade with an earnings beat and strong 2026 guidance that boosted bullish expectations from analysts.
GOOGL Price Target Raise, SNPS Strong Guidance, LLY Retratrutide Results
Oracle (ORCL) weighed on markets Thursday morning but Diane King Hall turns to stocks seeing strength. Synopsys (SNPS) added muscle to the tech trade with an earnings beat and strong 2026 guidance that boosted bullish expectations from analysts.
12/11 10:03 EST - 247wallst.com
Live Nasdaq Composite: Markets Retreat on AI Trade Fatigue
Live Updates AI Bubbles 12 minutes ago Live Deutsche Bank says AI is in not one but two bubbles and both are still in the early stages. One is driven by cash-rich Big Tech companies pouring profits into AI spending (ahem, Oracle), while the other sits in riskier, mostly private "frontier"...
Live Nasdaq Composite: Markets Retreat on AI Trade Fatigue
Live Updates AI Bubbles 12 minutes ago Live Deutsche Bank says AI is in not one but two bubbles and both are still in the early stages. One is driven by cash-rich Big Tech companies pouring profits into AI spending (ahem, Oracle), while the other sits in riskier, mostly private "frontier"...
12/11 09:15 EST - schaeffersresearch.com
Oracle, AI Stocks Put a Dent in Sentiment
Oracle (ORCL) is plummeting premarket, dragging the rest of the AI sector and weighing on the broader market
Oracle, AI Stocks Put a Dent in Sentiment
Oracle (ORCL) is plummeting premarket, dragging the rest of the AI sector and weighing on the broader market
12/11 07:55 EST - marketwatch.com
Eli Lilly's newest weight-loss drug relieved pain in patients with knee osteoarthritis
Eli Lilly's “triple g” drug helped patients lose about 28.7% of their body weight while also reducing pain associated with knee osteoarthritis in a Phase 3 trial.
Eli Lilly's newest weight-loss drug relieved pain in patients with knee osteoarthritis
Eli Lilly's “triple g” drug helped patients lose about 28.7% of their body weight while also reducing pain associated with knee osteoarthritis in a Phase 3 trial.
Market News
×
Loading news…